United Therapeutics Skyrockets 38.15%—What’s Fueling This Unprecedented Surge?

Summary
• United Therapeutics (UTHR) surges 38.15% intraday, hitting a 52-week high of $436.95
• Tyvaso trial win and Reuters report cite '40% rocket' as catalyst
• Intraday range spans $403.04 to $436.95, signaling explosive momentum

United Therapeutics has ignited a firestorm in the market, surging over 38% in a single session. The stock’s meteoric rise coincides with a reported trial victory for its lung disease drug and a Reuters headline labeling it a '40% rocket.' With the 52-week high now breached and turnover spiking to 1.47 million shares, the question is no longer if this move will continue—but how to position for the next phase.

Tyvaso Trial Win Ignites Investor Optimism
The surge is directly tied to United Therapeutics’ reported success in a key trial for Tyvaso, its pulmonary arterial hypertension drug. While the company’s investor relations page lacks specifics, a Reuters article (linked in the latest news) explicitly states the stock 'rockets 40%' on the back of this development. The 52-week high of $436.95—reached during today’s session—confirms the market’s bullish re-rating of the company’s pipeline and commercial potential.

Options Playbook: High-Leverage Calls for Aggressive Bulls
• MACD: 2.4159 (bullish divergence), Signal Line: 3.0692 (bearish crossover), Histogram: -0.6532 (negative momentum)
• RSI: 54.71 (neutral), Bollinger Bands: $295.06–$317.55 (far below current price), 200D MA: $324.71 (well below)

United Therapeutics is trading at a 29% premium to its 200-day average, with RSI hovering near neutral territory. The MACD histogram’s negative divergence suggests short-term profit-taking, but the 52-week high breakout and zero volume at key support levels (304.64–305.43) indicate strong conviction. For aggressive bulls, two options stand out:

• UTHR20251121C430
- Strike: $430, Expiration: 2025-11-21, IV: 7.51%, Leverage Ratio: 166.79%, Delta: 0.278994, Theta: -0.090043, Gamma: 0.022783, Turnover: 0
- IV (low volatility), Leverage (extreme), Delta (modest), Gamma (high sensitivity). This call offers explosive upside if UTHR holds above $430, with gamma amplifying gains as the stock rises.
• UTHR20251219C430
- Strike: $430, Expiration: 2025-12-19, IV: 12.89%, Leverage Ratio: 49.64%, Delta: 0.412225, Theta: -0.115883, Gamma: 0.013254, Turnover: 0
- IV (moderate), Leverage (modest), Delta (balanced), Theta (high time decay). This contract balances risk and reward, ideal for a mid-term hold if the stock consolidates after today’s breakout.

Payoff Estimation: A 5% upside to $442.09 would yield $12.09/share on the $430 call (UTHR20251121C430), translating to a 280% return. Aggressive bulls should prioritize the November 21st expiry for maximum leverage, while the December 19th expiry offers a safer, more liquid alternative. Hook: If $430 holds, UTHR20251121C430 could double in value by expiration.

Backtest United Therapeutics Stock Performance

Breakout Confirmed—Position for Next-Phase Gains
United Therapeutics’ 38% surge has validated its breakout above key resistance, with the 52-week high now acting as a psychological floor. While the MACD histogram hints at near-term profit-taking, the RSI’s neutrality and Bollinger Bands’ wide separation suggest the rally is far from over. Investors should monitor the $430 level as a critical support; a retest here could trigger a second wave. Meanwhile, sector leader Johnson & Johnson (JNJ) remains flat at +0.5%, underscoring UTHR’s standalone momentum. Action: Buy the November 21st $430 call for aggressive exposure or the December 19th expiry for a more conservative play. Watch for a $430 breakdown or regulatory follow-up on Tyvaso’s trial results.